Patents by Inventor Ellen Myra Dobrusin
Ellen Myra Dobrusin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7786131Abstract: The present invention relates to pyrimido [5,4-d] pyrimidine compounds of Formula II or a pharmaceutically acceptable salt thereof, wherein Q is and X, E1, E2, E3, R6 and p are as defined herein. The compounds of this invention are irreversible inhibitors of tyrosine kinases and are useful in the treatment of cancer, atherosclerosis, restenosis, endometriosis and psoriasis.Type: GrantFiled: May 20, 2003Date of Patent: August 31, 2010Assignee: Warner-Lambert CompanyInventors: Alexander James Bridges, William Alexander Denny, Ellen Myra Dobrusin, Annette Marian Doherty, David William Fry, Dennis Joseph McNamara, Howard Daniel Hollis Showalter, Jeffrey B. Smaill, Hairong Zhou
-
Patent number: 7501425Abstract: This invention provides substituted pyrimido-pyrimidines that are useful for treating cell proliferative disorders, such as cancer and restenosis, as well as angiogenesis and atherosclerosis. The invention compounds have Formula I: where W is NH, S, SO, or SO2, R1 includes alkyl, cycloalkyl, phenyl, substituted phenyl, heteroaryl and substituted heteroaryl; R2 includes alkyl, cycloalkyl, phenyl and substituted phenyl; R3 includes alkyl and aryl such as phenyl and substituted phenyl; R8 and R9 include hydrogen and alkyl, and the pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical formulations comprising a compound of Formula I together with a pharmaceutically acceptable carrier, diluent, or excipient therefor, and a method for treating angiogenesis using said compounds.Type: GrantFiled: May 10, 1999Date of Patent: March 10, 2009Assignee: Warner Lambert CompanyInventors: Ellen Myra Dobrusin, James Marino Hamby, James Bernard Kramer, Mel Conrad Schroeder, Howard Daniel Hollis Showalter, Peter Toogood, Susanne A. Trumpp-Kallmeyer
-
Patent number: 7094798Abstract: This invention relates to pyrrolocarbazole derivatives according formula I wherein R1, R2, R7, R8, R9, X and Y are as defined in the specification wherein said derivatives specifically inhibit one or both of the checkpoint kinases Wee1 and Chk1Type: GrantFiled: April 25, 2003Date of Patent: August 22, 2006Assignee: Pfizer IncInventors: Richard John Booth, Ellen Myra Dobrusin, Alan Kraker, Lorna Helen Mitchell, William Alexander Denny, Jeffrey Bruce Smaill, Andrew Mark Thompson, Florence Oliver Joseph McCarthy, Ho Huat Lee, Brian Desmond Palmer
-
Patent number: 7053070Abstract: Disclosed are compounds of the formula wherein R2, R5, R6, R7, and R8 are as defined herein. These compounds and their pharmaceutical compositions are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cdks and growth factor-mediated kinases.Type: GrantFiled: January 23, 2001Date of Patent: May 30, 2006Assignee: Warner-Lambert CompanyInventors: Richard John Booth, Ellen Myra Dobrusin, Vara Prasad Venkata Nagendra Josyula, Dennis Joseph Mc Namara, Peter Laurence Toogood
-
Patent number: 6982260Abstract: This invention provides quinazolines that are useful for treating cell proliferative diseases and disorders, such as cardiovascular diseases, infections, cancers, autoimmune diseases, gout, kidney disease, and neurodegenerative diseases and disorders such as Alzheimer's disease. We have now discovered a group of 2-arylamino-7-(alkyl)oxy-8-alkylquinazolines and 8-alkyl-2-arylamino-quinazoline 2,7-diamines that are potent inhibitors of cyclin-dependent kinases (cdks). The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention also provides pharmaceutical formulations comprising at least one of the quinazoline compounds together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. The invention further provide useful intermediates generated during the production of the quinazoline compounds.Type: GrantFiled: November 3, 2000Date of Patent: January 3, 2006Assignee: Warner-Lambert CompanyInventors: Mark Robert Barvian, Ellen Myra Dobrusin, James Stanley Kaltenbronn, Peter L. Toogood, Roy Thomas Winters, Inderjit S. Sidhu, Rajeshwar Singh, Yadagiri Bathini, Ronald George Micetich
-
Publication number: 20040044012Abstract: This invention provides bicyclic heterocycles that are useful for treating cell proliferative disorders, such as cancer and restenosis, as well as angiogenesis and atherosclerosis. We have now discovered a group of bicyclic compounds that are potent inhibitors of cyclin-dependent kinases (cdks), growth factor-mediated kinases, and non-receptor kinases. The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability for clinical use.Type: ApplicationFiled: August 11, 2003Publication date: March 4, 2004Inventors: Ellen Myra Dobrusin, James Marino Hamby, James Bernard Kramer, Mel Conrad Schroeder, Howard Daniel Hollis Showalter, Peter Toogood, Susanne A. Trumpp-Kallmeyer
-
Publication number: 20040006042Abstract: The present invention provides compounds of Formula II: 1Type: ApplicationFiled: May 28, 2003Publication date: January 8, 2004Inventors: David Allen Berry, Ellen Myra Dobrusin, Judith Lynne Johnson-Philipsen, Wayne Daniel Klohs, Dennis Joseph McNamara, Leslie Morton Werbel
-
Publication number: 20030229051Abstract: The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.Type: ApplicationFiled: May 20, 2003Publication date: December 11, 2003Inventors: Alexander James Bridges, William Alexander Denny, Ellen Myra Dobrusin, Annette Marian Doherty, David William Fry, Dennis Joseph McNamara, Howard Daniel Hollis Showalker, Jeffrey B. Smaill, Hairong Zhou
-
Patent number: 6602863Abstract: The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.Type: GrantFiled: September 27, 2000Date of Patent: August 5, 2003Assignee: Warner-Lambert CompanyInventors: Alexander James Bridges, William Alexander Denny, Ellen Myra Dobrusin, Annette Marian Doherty, David William Fry, Dennis Joseph McNamara, Howard Daniel Hollis Showalter, Jeffrey B. Smaill, Hairong Zhou
-
Publication number: 20030073668Abstract: Disclosed are compounds of the formula (I) wherein: R2, R7, RI3, R14 and R15 are independently hydrogen, or (un)substituted lower alkyl, (un)substitued lower alkenyl, (un)substituted lower alkynyl, or (un)substituted —(CH2)nR12; R5 is halogen, cyano, nitro, —R9, —NR9R10, or —OR9; R6 is halogen, cyano, nitro, —R9, —NR9R10, —OR9, —Co2R9, —COR9, —CONR9R10, —NR9COR10, (un)substiuted lower alkenyl, or (un)substituted lower alkynyl; R8 is —CO2R13, —COR13, —CONR13R14, —CSNR13R14, —C(NR13)NR14R15, —SO3R13, —SO2R13, —SO2NR13R14, —PO3R13R14, —POR13R14, —PO(NR13R14)2; R9 and R10 are independently hydrogen or (un)substituted lower alkyl; R11 is a heteroaryl or a heterocyclic group; R12 is a cycloalkyl, a heterocyclic, an aryl, or a heteroaryl group; and n is 0,1,2, or 3.Type: ApplicationFiled: July 24, 2002Publication date: April 17, 2003Inventors: Richard John Booth, Ellen Myra Dobrusin, Vara Prasad Venkata Nagendra Josyula, Dennis Joseph McNamara, Peter Laurence Toogood
-
Patent number: 6528535Abstract: The present invention provide compounds of Formula I The present invention also provides a method of treating cancer and treating or preventing restenosis or atherosclerosis. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula I.Type: GrantFiled: July 23, 2001Date of Patent: March 4, 2003Assignee: Warner-Lambert CompanyInventors: Jack Bikker, Ellen Myra Dobrusin, Annette Marian Doherty, Matthew Drowns, James Stanley Kaltenbronn, Juergen Kleinschroth, Dennis Joseph McNamara, John Quin, III, Joseph Thomas Repine, Marcin Stasiak
-
Patent number: 6498163Abstract: This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferative disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2-(amino and thio)pyrido[2,3-d]pyrimidines and 2,4-diaminopyrimidines that are potent inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases. The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention provides compounds of Formula I: and Formula II: where W is NH, S, SO, or SO2, R1 includes phenyl and substituted phenyl, R2 includes alkyl and cycloalkyl, R3 includes alkyl and hydrogen, R8 and R9 include hydrogen and alkyl, and Z is carboxy. This invention also provides pharmaceutical formulations comprising a compound of Formula I or II together with a pharmaceutically acceptable carrier, diluent, or excipient therefor.Type: GrantFiled: August 2, 1999Date of Patent: December 24, 2002Assignee: Warner-Lambert CompanyInventors: Diane Harris Boschelli, Annette Marian Doherty, Ali Fattaey, David William Fry, Susanne Andrea Trumpp-Kallmeyer, Zhipei Wu, Ellen Myra Dobrusin, Mark Robert Barvian
-
Patent number: 6344459Abstract: The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.Type: GrantFiled: June 8, 1999Date of Patent: February 5, 2002Assignee: Warner-Lambert CompanyInventors: Alexander James Bridges, William Alexander Denny, Ellen Myra Dobrusin, Annette Marian Doherty, David William Fry, Dennis Joseph McNamara, Howard Daniel Hollis Showalter, Jeffrey B. Smaill, Hairong Zhou
-
Publication number: 20020006936Abstract: The present invention provides compounds of Formula I 1Type: ApplicationFiled: July 23, 2001Publication date: January 17, 2002Inventors: Jack Bikker, Ellen Myra Dobrusin, Annette Marian Doherty, Matthew Drowns, James Stanley Kaltenbronn, Juergen Kleinschroth, Dennis Joseph McNamara, John Quin, Joseph Thomas Repine, Marcin Stasiak
-
Patent number: 6265422Abstract: The present invention provides compounds of Formula I The present invention also provides a method of treating cancer and treating or preventing restenosis or atherosclerosis. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula I.Type: GrantFiled: April 28, 2000Date of Patent: July 24, 2001Assignee: Warner-Lambert CompanyInventors: Jack Bikker, Ellen Myra Dobrusin, Annette Marian Doherty, Matthew Drowns, James Stanley Kaltenbronn, Juergen Kleinschroth, Dennis Joseph McNamara, John Quin, III, Joseph Thomas Repine, Marcin Stasiak
-
Patent number: 6150359Abstract: This invention relates to the inhibition of protein tyrosine kinase (PTK) and cell cycle kinase mediated cellular proliferation. More specifically, this invention relates to naphthyridinones and their use in inhibiting cellular proliferation and PTK or cell cycle kinase enzymatic activity.Type: GrantFiled: January 26, 2000Date of Patent: November 21, 2000Assignee: Warner-Lambert CompanyInventors: Mark Robert Barvian, William Alexander Denny, Ellen Myra Dobrusin, James Marino Hamby, Howard Daniel Hollis Showalter, Andrew Mark Thompson, Roy Thomas Winters, Zhipei Wu
-
Patent number: 6133303Abstract: The present invention provides compounds of Formula (I). The present invention also provides a method of treating cancer and treating or preventing restenosis or atherosclerosis. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula (I).Type: GrantFiled: August 2, 1999Date of Patent: October 17, 2000Assignee: Warner-Lambert CompanyInventors: Jack Bikker, Ellen Myra Dobrusin, Annette Marian Doherty, Matthew Drowns, James Stanley Kaltenbronn, Juergen Kleinschroth, Dennis Joseph McNamara, John Quin, III, Joseph Thomas Repine, Marcin Stasiak